Please use this identifier to cite or link to this item:
|Title:||Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.|
|Authors:||Charles, Patrick G P;Ward, Peter B;Johnson, Paul D R;Howden, Benjamin P;Grayson, M Lindsay|
|Affiliation:||Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia. email@example.com|
|Citation:||Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2004; 38(3): 448-51|
|Abstract:||We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.|
|Internal ID Number:||14727222|
|Subjects:||Anti-Bacterial Agents.pharmacology.therapeutic use|
Drug Resistance, Bacterial
Staphylococcal Infections.drug therapy.microbiology
Staphylococcus aureus.drug effects
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.